anticoagulants, vitamin K antagonists, warfarin, thromboembolic disease
DISEASE INTERVENTION COMPARISON RESULTS
Ann Intern Med. 2003 May 6;138(9):714-9 Randomized Controlled Trial
IN anticoagulants, vitamin K antagonists, warfarin, thromboembolic disease The Use of
higher starting dose: 10 mg/day
As Treatment, Acute
Is better Than
usual starting dose: 5 mg/day
To reduce time to achieve therapeutic INR at day 5 (83% with 10mg VS 46% with 5mg, overall reduction by 1.5 days). No significant differences in major bleeding, coagulation excess (INR > 5.0), recurrent events and survival.